TAVI is increasingly adopted as standard treatment for many subgroups of patients with aortic stenosis. However, due to a lack of data there is yet no TAVI-specific guidance regarding the optimum periinterventional drug regimen. The study evaluates the effect of dual antiplatelet pretreatment on periinterventional embolic cerebral lesions and bleeding complications in patients undergoing transfemoral aortic valve implantation (TF-TAVI).
Patients undergoing TAVI bear a high risk of ischaemic stroke, which is an independent predictor of mortality1. Dual antiplatelet therapy (DAPT) is recommended by current guidelines without clear specifications on the time of initiation of treatment due to a lack of data. While some centers initiate DAPT with aspirin and clopidogrel prior to TAVI to reduce the rate of periinterventional embolic events, others start these medications after the procedure.Data on antithrombotic therapy during TAVI are scarce and no randomized evaluation has been performed to demonstrate what the best strategy is during the procedure. Therefore, the objective of this clinical trial is to assess the efficacy of pre- versus postoperative dual antiplatelet loading with Aspirin and Clopidogrel on volume of periinterventional cerebral ischemic lesions as quantified by diffusion weight MRI (DW-MRI) and neurocognitive function in patients undergoing transfemoral aortic valve replacement. The statistical trial design assumes superiority of preloading with DAPT regarding the primary endpoint.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
200
Preloading with Aspirin and Clopidogrel before TAVI
Postloading with Aspirin and Clopidogrel after TAVI
Total volume of new cerebral lesions on MRI after TAVI versus Baseline
Time frame: Total volume of new cerebral lesions on MRI, 24-72h after TAV versus Baseline
New lesion volume of cerebral embolization in patients treated with ASS and Clopidogrel before versus after TAVI
Total new lesion volume is defined as the sum volume of all new cerebral ischemic lesions on the post-procedural MRI relative to the pre-TAVR cerebral MRI scan (on diffusion weighted and FLAIR MRI images).
Time frame: 24-72h post TAVI versus baseline
location of new cerebral lesions early AFTER TAVI
To evaluate cerebral embolisation, which is not procedure related, cerebral embolisation on MRI will be before TAVI versus the post-TAVI MRI scan
Time frame: 24-72h after TAVI
extent of new cerebral lesions early AFTER TAVI
To evaluate cerebral embolisation, which is not procedure related, cerebral embolisation on MRI will be before TAVI versus the post-TAVI MRI scan
Time frame: 24-72h after TAVI
Assessment of different neurocognitive tests before and after TAVI procedure
To evaluate neurologic function with a battery of neurocognitive tests and to correlate these findings to cerebral MRI scans
Time frame: 24-72 h after TAVI
Extent of clinically apparent non-cerebral emboli after TAVI
To describe extent and localization of non-cerebral embolisation (e.g. pulmonary embolism, limb ischaemia...)
Time frame: 24-72 h after TAVI
localization of clinically apparent non-cerebral emboli after TAVI
To describe extent and localization of non-cerebral embolisation (e.g. pulmonary embolism, limb ischaemia...)
Time frame: 24-72 h after TAVI
Evaluation of possible changes in quality of life after TAVI with EQ-5D questionnaire sum score.
Time frame: 24-72 h after TAVI
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.